Radium-223 Chloride (Alpharadin) is now available for the treatment of men with advanced prostate cancer who have symptomatic bone metastases (painful) and who are also castration-resistant (hormone-refractory). This is an expanded access program that will allow the use of Alpharadin prior to the formal FDA approval of the treatment. From the Clinical Trials Web Page [...]
Those are the words of Warren Buffet, and from what has been published about his prostate cancer, he might be in a better seat if he was in one of those dry spells re ideas about treatment... and I keep pulling my hair out wondering what national advocacy groups are doing. Will they rise to [...]
Yesterday May 16, 2012, the House Appropriations Committee released their draft committee report to accompany the FY13 Defense Appropriations Act. This draft included the CDMRP requested budget for 2013. The good news is that the ask includes $80 million dollars for the Prostate Cancer Research Program. Although this is the same amount prostate cancer received [...]
Today, May 16, 2012, Dendreon, the makers of Provenge, disclosed a new analysis of data of its pivotal 512-patient study of men with castrate resistant prostate cancer who received sipuleucel-T (Provenge). The new analysis separated the men in the study into four quartiles based on their prostate-specific antigen (PSA) scores. The initial design of the [...]
Just reflecting on an incident last year. I was out for a jog in my neighborhood, I saw a young family out for a walk... always a wonderful thing to see. The young daughter got something in her eye and began to cry. Both parents immediately rushed to her, letting go of the baby stroller [...]